Definium Therapeutics Expands Investor Engagement Following Positive Phase 3 LSD Trial Results
The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...
The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...
Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
